| Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine A Mathian, M Mahevas, J Rohmer, M Roumier, F Cohen-Aubart, ... Annals of the rheumatic diseases 79 (6), 837-839, 2020 | 271 | 2020 |
| COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study J Avouac, E Drumez, E Hachulla, R Seror, S Georgin-Lavialle, ... The Lancet Rheumatology 3 (6), e419-e426, 2021 | 245 | 2021 |
| Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients S Georgin‐Lavialle, B Terrier, AF Guedon, M Heiblig, T Comont, E Lazaro, ... British Journal of Dermatology 186 (3), 564-574, 2022 | 210 | 2022 |
| Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients A Mekinian, C Comarmond, M Resche-Rigon, T Mirault, JE Kahn, ... Circulation 132 (18), 1693-1700, 2015 | 204 | 2015 |
| Lupus enteritis: from clinical findings to therapeutic management P Janssens, L Arnaud, L Galicier, A Mathian, M Hie, D Sene, J Haroche, ... Orphanet journal of rare diseases 8, 1-10, 2013 | 178 | 2013 |
| Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura M Hie, J Gay, L Galicier, F Provôt, C Presne, P Poullin, G Bonmarchand, ... Blood, The Journal of the American Society of Hematology 124 (2), 204-210, 2014 | 167 | 2014 |
| A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP P Coppo, M Bubenheim, E Azoulay, L Galicier, S Malot, N Bigé, P Poullin, ... Blood, The Journal of the American Society of Hematology 137 (6), 733-742, 2021 | 134 | 2021 |
| Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura M Jestin, Y Benhamou, AS Schelpe, E Roose, F Provôt, L Galicier, M Hié, ... Blood, The Journal of the American Society of Hematology 132 (20), 2143-2153, 2018 | 126 | 2018 |
| Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial A Mathian, M Pha, J Haroche, F Cohen-Aubart, M Hié, MP de Chambrun, ... Annals of the Rheumatic Diseases 79 (3), 339-346, 2020 | 122 | 2020 |
| Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions A Mathian, C Parizot, K Dorgham, S Trad, L Arnaud, M Larsen, M Miyara, ... Annals of the rheumatic diseases 71 (7), 1227-1234, 2012 | 109 | 2012 |
| Coronavirus disease 2019 acute myocarditis and multisystem inflammatory syndrome in adult intensive and cardiac care units G Hékimian, M Kerneis, M Zeitouni, F Cohen-Aubart, J Chommeloux, ... Chest 159 (2), 657-662, 2021 | 106 | 2021 |
| Relapsing polychondritis: a 2016 update on clinical features, diagnostic tools, treatment and biological drug use A Mathian, M Miyara, F Cohen-Aubart, J Haroche, M Hie, M Pha, ... Best practice & research Clinical rheumatology 30 (2), 316-333, 2016 | 105 | 2016 |
| Lupus myocarditis: initial presentation and longterm outcomes in a multicentric series of 29 patients G Thomas, FC Aubart, L Chiche, J Haroche, M Hié, B Hervier, ... The Journal of rheumatology 44 (1), 24-32, 2017 | 101 | 2017 |
| Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature E Zard, L Arnaud, A Mathian, Z Chakhtoura, M Hie, P Touraine, I Heard, ... Autoimmunity reviews 13 (7), 730-735, 2014 | 101 | 2014 |
| Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression Y Allenbach, G Leroux, X Suárez-Calvet, C Preusse, E Gallardo, ... The American Journal of Pathology 186 (3), 691-700, 2016 | 97 | 2016 |
| Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil S Bitoun, D Bouvry, R Borie, M Mahevas, K Sacre, J Haroche, D Psimaras, ... Neurology 87 (24), 2517-2521, 2016 | 95 | 2016 |
| Long-term outcomes of refractory neurosarcoidosis treated with infliximab F Cohen Aubart, D Bouvry, D Galanaud, C Dehais, G Mathey, D Psimaras, ... Journal of neurology 264, 891-897, 2017 | 93 | 2017 |
| Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors Annals of the Rheumatic Diseases 80 (4), 527-538, 2021 | 86 | 2021 |
| Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases T de Risi-Pugliese, FC Aubart, J Haroche, P Moguelet, ... Seminars in arthritis and rheumatism 48 (1), 83-89, 2018 | 85 | 2018 |
| Sjögren sensory neuronopathy (Sjögren ganglionopathy): long-term outcome and treatment response in a series of 13 cases PR Pereira, K Viala, T Maisonobe, J Haroche, A Mathian, M Hié, ... Medicine 95 (19), e3632, 2016 | 83 | 2016 |
